The  ||| S:0 E:4 ||| DT
role  ||| S:4 E:9 ||| NN
of  ||| S:9 E:12 ||| IN
i.v.  ||| S:12 E:17 ||| CD
ibandronate  ||| S:17 E:29 ||| JJ
administration  ||| S:29 E:44 ||| NN
in  ||| S:44 E:47 ||| IN
osteoporosis  ||| S:47 E:60 ||| JJ
therapy  ||| S:60 E:68 ||| NN
Osteoporosis  ||| S:68 E:81 ||| NNP
is  ||| S:81 E:84 ||| VBZ
a  ||| S:84 E:86 ||| DT
chronic  ||| S:86 E:94 ||| JJ
disease  ||| S:94 E:102 ||| NN
of  ||| S:102 E:105 ||| IN
the  ||| S:105 E:109 ||| DT
osseous  ||| S:109 E:117 ||| JJ
system  ||| S:117 E:124 ||| NN
characterised  ||| S:124 E:138 ||| NN
by  ||| S:138 E:141 ||| IN
decreased  ||| S:141 E:151 ||| JJ
strength  ||| S:151 E:160 ||| NN
of  ||| S:160 E:163 ||| IN
bone  ||| S:163 E:168 ||| NN
tissue ||| S:168 E:174 ||| NN
,  ||| S:174 E:176 ||| ,
which  ||| S:176 E:182 ||| WDT
in  ||| S:182 E:185 ||| IN
turn  ||| S:185 E:190 ||| NN
leads  ||| S:190 E:196 ||| VBZ
to  ||| S:196 E:199 ||| TO
increased  ||| S:199 E:209 ||| VB
fracture  ||| S:209 E:218 ||| JJ
risk ||| S:218 E:222 ||| NN
.  ||| S:222 E:224 ||| .
It  ||| S:224 E:227 ||| PRP
has  ||| S:227 E:231 ||| VBZ
been  ||| S:231 E:236 ||| VBN
demonstrated  ||| S:236 E:249 ||| VBN
that  ||| S:249 E:254 ||| IN
osteoporosis  ||| S:254 E:267 ||| NN
affects  ||| S:267 E:275 ||| VBZ
more  ||| S:275 E:280 ||| JJR
than  ||| S:280 E:285 ||| IN
30 ||| S:285 E:287 ||| CD
%  ||| S:287 E:289 ||| NN
of  ||| S:289 E:292 ||| IN
women  ||| S:292 E:298 ||| NNS
after  ||| S:298 E:304 ||| IN
the  ||| S:304 E:308 ||| DT
menopause  ||| S:308 E:318 ||| NN
( ||| S:318 E:319 ||| -LRB-
World  ||| S:319 E:325 ||| NNP
Health  ||| S:325 E:332 ||| NNP
Organization ||| S:332 E:344 ||| NNP
,  ||| S:344 E:346 ||| ,
1994 ||| S:346 E:350 ||| CD
) ||| S:350 E:351 ||| -RRB-
.  ||| S:351 E:353 ||| .
However ||| S:353 E:360 ||| RB
,  ||| S:360 E:362 ||| ,
the  ||| S:362 E:366 ||| DT
disease  ||| S:366 E:374 ||| NN
is  ||| S:374 E:377 ||| VBZ
also  ||| S:377 E:382 ||| RB
observed  ||| S:382 E:391 ||| VBN
in  ||| S:391 E:394 ||| IN
men ||| S:394 E:397 ||| NNS
.  ||| S:397 E:399 ||| .
The  ||| S:399 E:403 ||| DT
primary  ||| S:403 E:411 ||| JJ
goals  ||| S:411 E:417 ||| NNS
of  ||| S:417 E:420 ||| IN
osteoporosis  ||| S:420 E:433 ||| JJ
therapy  ||| S:433 E:441 ||| NN
include  ||| S:441 E:449 ||| VBP
prevention  ||| S:449 E:460 ||| VBN
of  ||| S:460 E:463 ||| IN
low-energy  ||| S:463 E:474 ||| JJ
fractures  ||| S:474 E:484 ||| NN
and  ||| S:484 E:488 ||| CC
general  ||| S:488 E:496 ||| JJ
improvement  ||| S:496 E:508 ||| NN
of  ||| S:508 E:511 ||| IN
quality  ||| S:511 E:519 ||| NN
of  ||| S:519 E:522 ||| IN
life ||| S:522 E:526 ||| NN
.  ||| S:526 E:528 ||| .
Any  ||| S:528 E:532 ||| DT
patient  ||| S:532 E:540 ||| NN
with  ||| S:540 E:545 ||| IN
diagnosed  ||| S:545 E:555 ||| JJ
osteoporosis  ||| S:555 E:568 ||| NN
requires ||| S:568 E:576 ||| VBZ
,  ||| S:576 E:578 ||| ,
besides  ||| S:578 E:586 ||| IN
prevention ||| S:586 E:596 ||| NN
,  ||| S:596 E:598 ||| ,
the  ||| S:598 E:602 ||| DT
application  ||| S:602 E:614 ||| NN
of  ||| S:614 E:617 ||| IN
proper  ||| S:617 E:624 ||| JJ
treatment ||| S:624 E:633 ||| NN
.  ||| S:633 E:635 ||| .
Of  ||| S:635 E:638 ||| IN
the  ||| S:638 E:642 ||| DT
available  ||| S:642 E:652 ||| JJ
therapeutic  ||| S:652 E:664 ||| JJ
options ||| S:664 E:671 ||| NNS
,  ||| S:671 E:673 ||| ,
the  ||| S:673 E:677 ||| DT
best  ||| S:677 E:682 ||| JJS
are  ||| S:682 E:686 ||| VBP
bisphosphonates ||| S:686 E:701 ||| VBN
,  ||| S:701 E:703 ||| ,
medical  ||| S:703 E:711 ||| JJ
agents  ||| S:711 E:718 ||| NNS
with  ||| S:718 E:723 ||| IN
well  ||| S:723 E:728 ||| RB
identified  ||| S:728 E:739 ||| VBN
properties ||| S:739 E:749 ||| NNS
,  ||| S:749 E:751 ||| ,
therapeutic  ||| S:751 E:763 ||| JJ
efficacy ||| S:763 E:771 ||| NN
,  ||| S:771 E:773 ||| ,
and  ||| S:773 E:777 ||| CC
safety  ||| S:777 E:784 ||| NN
which  ||| S:784 E:790 ||| WDT
has  ||| S:790 E:794 ||| VBZ
been  ||| S:794 E:799 ||| VBN
confirmed  ||| S:799 E:809 ||| VBN
in  ||| S:809 E:812 ||| IN
many  ||| S:812 E:817 ||| JJ
clinical  ||| S:817 E:826 ||| JJ
studies ||| S:826 E:833 ||| NNS
.  ||| S:833 E:835 ||| .
Therefore ||| S:835 E:844 ||| RB
,  ||| S:844 E:846 ||| ,
they  ||| S:846 E:851 ||| PRP
are  ||| S:851 E:855 ||| VBP
recommended  ||| S:855 E:867 ||| VBN
as  ||| S:867 E:870 ||| IN
first  ||| S:870 E:876 ||| JJ
line  ||| S:876 E:881 ||| NN
drugs  ||| S:881 E:887 ||| NNS
for  ||| S:887 E:891 ||| IN
osteoporosis ||| S:891 E:903 ||| NN
.  ||| S:903 E:905 ||| .
The  ||| S:905 E:909 ||| DT
efficacy  ||| S:909 E:918 ||| NN
of  ||| S:918 E:921 ||| IN
oral  ||| S:921 E:926 ||| JJ
preparations  ||| S:926 E:939 ||| NNS
may  ||| S:939 E:943 ||| MD
be  ||| S:943 E:946 ||| VB
limited ||| S:946 E:953 ||| VBN
,  ||| S:953 E:955 ||| ,
due  ||| S:955 E:959 ||| JJ
to  ||| S:959 E:962 ||| TO
low  ||| S:962 E:966 ||| JJ
bioavailability ||| S:966 E:981 ||| NN
,  ||| S:981 E:983 ||| ,
complications  ||| S:983 E:997 ||| NNS
and  ||| S:997 E:1001 ||| CC
adverse  ||| S:1001 E:1009 ||| JJ
effects  ||| S:1009 E:1017 ||| NNS
from  ||| S:1017 E:1022 ||| IN
the  ||| S:1022 E:1026 ||| DT
gastrointestinal  ||| S:1026 E:1043 ||| JJ
tract ||| S:1043 E:1048 ||| NN
.  ||| S:1048 E:1050 ||| .
So  ||| S:1050 E:1053 ||| IN
the  ||| S:1053 E:1057 ||| DT
parenteral  ||| S:1057 E:1068 ||| JJ
administration  ||| S:1068 E:1083 ||| NN
of  ||| S:1083 E:1086 ||| IN
bisphosphonates  ||| S:1086 E:1102 ||| NN
is  ||| S:1102 E:1105 ||| VBZ
a  ||| S:1105 E:1107 ||| DT
valuable  ||| S:1107 E:1116 ||| JJ
alternative ||| S:1116 E:1127 ||| NN
.  ||| S:1127 E:1129 ||| .
A  ||| S:1129 E:1131 ||| DT
fine  ||| S:1131 E:1136 ||| JJ
example  ||| S:1136 E:1144 ||| NN
of  ||| S:1144 E:1147 ||| IN
such  ||| S:1147 E:1152 ||| JJ
therapy  ||| S:1152 E:1160 ||| NN
is  ||| S:1160 E:1163 ||| VBZ
the  ||| S:1163 E:1167 ||| DT
intravenous  ||| S:1167 E:1179 ||| JJ
administration  ||| S:1179 E:1194 ||| NN
of  ||| S:1194 E:1197 ||| IN
ibandronate ||| S:1197 E:1208 ||| NN
.  ||| S:1208 E:1210 ||| .
Short  ||| S:1210 E:1216 ||| JJ
injection  ||| S:1216 E:1226 ||| NN
time  ||| S:1226 E:1231 ||| NN
periods  ||| S:1231 E:1239 ||| NNS
and  ||| S:1239 E:1243 ||| CC
the  ||| S:1243 E:1247 ||| DT
relatively  ||| S:1247 E:1258 ||| RB
long ||| S:1258 E:1262 ||| RB
,  ||| S:1262 E:1264 ||| ,
three-month  ||| S:1264 E:1276 ||| JJ
intervals  ||| S:1276 E:1286 ||| NNS
between  ||| S:1286 E:1294 ||| IN
administrations  ||| S:1294 E:1310 ||| NNS
are  ||| S:1310 E:1314 ||| VBP
unquestionable  ||| S:1314 E:1329 ||| JJ
advantages  ||| S:1329 E:1340 ||| NNS
of  ||| S:1340 E:1343 ||| IN
this  ||| S:1343 E:1348 ||| DT
therapy  ||| S:1348 E:1356 ||| NN
mode ||| S:1356 E:1360 ||| NN
.  ||| S:1360 E:1362 ||| .
In  ||| S:1362 E:1365 ||| IN
addition ||| S:1365 E:1373 ||| NN
,  ||| S:1373 E:1375 ||| ,
the  ||| S:1375 E:1379 ||| DT
therapy  ||| S:1379 E:1387 ||| NN
does  ||| S:1387 E:1392 ||| VBZ
not  ||| S:1392 E:1396 ||| RB
constrain  ||| S:1396 E:1406 ||| VB
a  ||| S:1406 E:1408 ||| DT
patient ||| S:1408 E:1415 ||| NN
's  ||| S:1415 E:1418 ||| POS
everyday  ||| S:1418 E:1427 ||| JJ
activity ||| S:1427 E:1435 ||| NN
,  ||| S:1435 E:1437 ||| ,
and  ||| S:1437 E:1441 ||| CC
simultaneously  ||| S:1441 E:1456 ||| RB
provides  ||| S:1456 E:1465 ||| VBZ
regular  ||| S:1465 E:1473 ||| JJ
contact  ||| S:1473 E:1481 ||| NN
with  ||| S:1481 E:1486 ||| IN
doctors  ||| S:1486 E:1494 ||| NNS
and  ||| S:1494 E:1498 ||| CC
the  ||| S:1498 E:1502 ||| DT
therapeutic  ||| S:1502 E:1514 ||| JJ
centre ||| S:1514 E:1520 ||| NN
.  ||| S:1520 E:1522 ||| .
Additionally ||| S:1522 E:1534 ||| RB
,  ||| S:1534 E:1536 ||| ,
a  ||| S:1536 E:1538 ||| DT
good  ||| S:1538 E:1543 ||| JJ
tolerance  ||| S:1543 E:1553 ||| NN
of  ||| S:1553 E:1556 ||| IN
the  ||| S:1556 E:1560 ||| DT
drug  ||| S:1560 E:1565 ||| NN
and  ||| S:1565 E:1569 ||| CC
its  ||| S:1569 E:1573 ||| PRP$
high  ||| S:1573 E:1578 ||| JJ
therapeutic  ||| S:1578 E:1590 ||| JJ
efficacy ||| S:1590 E:1598 ||| NN
,  ||| S:1598 E:1600 ||| ,
proven  ||| S:1600 E:1607 ||| VBN
by  ||| S:1607 E:1610 ||| IN
appreciably  ||| S:1610 E:1622 ||| RB
reduced  ||| S:1622 E:1630 ||| VBN
fracture  ||| S:1630 E:1639 ||| JJ
risks ||| S:1639 E:1644 ||| NNS
,  ||| S:1644 E:1646 ||| ,
significantly  ||| S:1646 E:1660 ||| RB
improves  ||| S:1660 E:1669 ||| VBZ
the  ||| S:1669 E:1673 ||| DT
quality  ||| S:1673 E:1681 ||| NN
of  ||| S:1681 E:1684 ||| IN
life  ||| S:1684 E:1689 ||| NN
of  ||| S:1689 E:1692 ||| IN
patients  ||| S:1692 E:1701 ||| NNS
suffering  ||| S:1701 E:1711 ||| VBG
from  ||| S:1711 E:1716 ||| IN
osteoporosis ||| S:1716 E:1728 ||| NN
.  ||| S:1728 E:1730 ||| .
This  ||| S:1730 E:1735 ||| DT
paper  ||| S:1735 E:1741 ||| NN
is  ||| S:1741 E:1744 ||| VBZ
a  ||| S:1744 E:1746 ||| DT
thorough  ||| S:1746 E:1755 ||| JJ
review  ||| S:1755 E:1762 ||| NN
of  ||| S:1762 E:1765 ||| IN
current  ||| S:1765 E:1773 ||| JJ
knowledge  ||| S:1773 E:1783 ||| NN
on  ||| S:1783 E:1786 ||| IN
the  ||| S:1786 E:1790 ||| DT
efficacy  ||| S:1790 E:1799 ||| NN
and  ||| S:1799 E:1803 ||| CC
safety  ||| S:1803 E:1810 ||| NN
of  ||| S:1810 E:1813 ||| IN
i.v.  ||| S:1813 E:1818 ||| CD
ibandronate  ||| S:1818 E:1830 ||| NN
in  ||| S:1830 E:1833 ||| IN
osteoporosis  ||| S:1833 E:1846 ||| JJ
therapy ||| S:1846 E:1853 ||| NN
,  ||| S:1853 E:1855 ||| ,
as  ||| S:1855 E:1858 ||| RB
presented  ||| S:1858 E:1868 ||| VBN
in  ||| S:1868 E:1871 ||| IN
the  ||| S:1871 E:1875 ||| DT
latest  ||| S:1875 E:1882 ||| JJS
literature  ||| S:1882 E:1893 ||| NN
reports ||| S:1893 E:1900 ||| NNS
.  ||| S:1900 E:1902 ||| .
